OncoMatch/Clinical Trials/NCT07094113
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Is NCT07094113 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including AMG 410 and Pembrolizumab for kras altered advanced or metastatic solid tumors.
Treatment: AMG 410 · Pembrolizumab · Panitumumab — The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult participants with KRAS-altered advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS amplification
Required: KRAS missense mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: within 28 days of first dose
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 28 days of first dose of study treatment
Cannot have received: antibody therapy
Exception: within 28 days of first dose
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 28 days of first dose of study treatment
Cannot have received: molecular targeted therapy
Exception: within 28 days of first dose
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 28 days of first dose of study treatment
Cannot have received: hormonal therapy
Exception: within 28 days of first dose
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 28 days of first dose of study treatment
Cannot have received: investigational agent
Exception: within 28 days of first dose
Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, hormonal therapy, or investigational agent) within 28 days of first dose of study treatment
Cannot have received: radiation therapy
Exception: within 2 weeks of first dose
Therapeutic or palliative radiation therapy within 2 weeks of first dose of study treatment
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- Emory University · Atlanta, Georgia
- Massachusetts General Hospital · Boston, Massachusetts
- Siteman Cancer Center - Washington University · St Louis, Missouri
- Duke Cancer Center · Durham, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07094113 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, antibody therapy, molecular targeted therapy disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS amplification is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS missense mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify